Trulieve Cannabis Corp. Share Price OTC Markets

Equities

TCNNF

CA89788C1041

Pharmaceuticals

Market Closed - OTC Markets 01:30:00 29/06/2024 am IST 5-day change 1st Jan Change
9.25 USD -11.99% Intraday chart for Trulieve Cannabis Corp. -0.43% +77.54%
Sales 2024 * 1.19B 98.81B Sales 2025 * 1.25B 104B Capitalization 1.74B 145B
Net income 2024 * -79M -6.58B Net income 2025 * -26M -2.17B EV / Sales 2024 * 1.6 x
Net Debt 2024 * 156M 13.04B Net cash position 2025 * 145M 12.08B EV / Sales 2025 * 1.28 x
P/E ratio 2024 *
-20.7 x
P/E ratio 2025 *
-60.3 x
Employees 5,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.92%
More Fundamentals * Assessed data
Dynamic Chart
Trulieve Cannabis Corp. Announces Opening of New Medical Cannabis Dispensary in Brooksville, Florida CI
Trulieve Cannabis Announced Litigation Settlement and Acquisition of Ohio Assets MT
Trulieve Cannabis Brief: Announced Litigation Settlement and Acquisition of Ohio Assets; Adds two medical dispensaries in Beavercreek and Columbus to Ohio footprint MT
Trulieve Cannabis Corp. agreed to acquire Harvest of Ohio LLC from Ariane Kirkpatrick. CI
Trulieve Cannabis Corp. agreed to acquire Harvest of Ohio LLC from Ariane Kirkpatrick. CI
Pot stocks rise as US unveils proposal to ease restrictions on marijuana RE
Trulieve to Open Medical Cannabis Dispensary in Stuart, Florida CI
Trulieve Cannabis' quarterly loss narrows on demand boost RE
Transcript : Trulieve Cannabis Corp., Q1 2024 Earnings Call, May 09, 2024
Trulieve Cannabis' quarterly loss narrows on demand boost RE
Trulieve Cannabis Brief: Citing "Definitive progress made" on Smart and Safe Florida adult use initiative and federal rescheduling of cannabis to Schedule III MT
Trulieve Cannabis Brief: Citing Q1 Strong cash flow from operations of US$139 million and free cash flow of $124 million in Q1 2024 MT
Trulieve Cannabis Brief: Citing Q1 US$298 million in revenue, up 4% sequentially, and 58% gross margin MT
Earnings Flash (TCNNF) TRULIEVE CANNABIS Reports Q1 Revenue $297.6M MT
Trulieve Cannabis Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
More news
1 day-11.99%
1 week-0.43%
Current month-5.42%
1 month-3.65%
3 months-25.40%
6 months+77.54%
Current year+77.54%
More quotes
1 week
9.01
Extreme 9.01
10.80
1 month
8.26
Extreme 8.26
10.80
Current year
5.04
Extreme 5.036
14.50
1 year
3.42
Extreme 3.42
14.50
3 years
3.42
Extreme 3.42
39.01
5 years
3.42
Extreme 3.42
53.73
10 years
3.42
Extreme 3.42
53.73
More quotes
Managers TitleAgeSince
Chief Executive Officer - 17/40/17
Director of Finance/CFO - 01/18/01
Chief Tech/Sci/R&D Officer - 17/21/17
Members of the board TitleAgeSince
Director/Board Member 65 10/21/10
Director/Board Member 70 02/20/02
Director/Board Member 72 15/19/15
More insiders
Date Price Change Volume
28/24/28 9.25 -11.99% 735,782
27/24/27 10.51 +6.16% 861,004
26/24/26 9.9 +0.51% 347,814
25/24/25 9.85 -0.71% 165,048
24/24/24 9.92 +6.78% 400,153

Delayed Quote OTC Markets, June 29, 2024 at 01:30 am IST

More quotes
Trulieve Cannabis Corp. is a vertically integrated cannabis company. The Company has established cannabis operations in three hubs: Southeast, Northeast, and Southwest. Its three regional hubs are anchored by market positions in cornerstone states of Florida, Pennsylvania, and Arizona. The Company operates in regulated markets that require knowledge in cultivation, manufacturing, and retail. The Company utilizes various extraction techniques, including critical ethanol extraction, carbon dioxide extraction, hydrocarbon extraction, and mechanical separation. In addition, the Company owns and utilizes carbon dioxide extraction, distillation, purification and manufacturing technology that is used to produce a range of cannabis topicals and vapes featuring cannabinoids. The Company's brands include premium tier brands Avenue, Cultivar Collection, and Muse; mid-tier brands Modern Flower, Alchemy, Momenta, and Sweet Talk, and value tier brands Co2lors, Loveli, Roll One, and Trekkers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
9.301 USD
Average target price
18.67 USD
Spread / Average Target
+100.69%
Consensus